Novel ADC Achieves Impressive PFS Advantage In HER2-Low Metastatic Breast Cancer
In China’s phase III APEX-Breast01 trial, TQB2102 extended median PFS to 16.4 months versus 5.5 months with chemotherapy; survival data remain preliminary.
Sixty and Me outlines five daily habits for pelvic health after 60, but its exercise and footwear recommendations are not a substitute for medical care.
Chinese Drug Shows Benefit In HER2-Low Breast Cancer
A China-based phase III trial found longer progression-free survival with trastuzumab rezetecan than chemotherapy, alongside more serious treatment-related harms.
Hip Fracture In Older Adults Is Far More Than An Orthopedic Injury
A Umeå University thesis finds health, dementia, psychological well-being and daily function are linked to hip fracture risk, mortality and recovery in adults 85+.